Dr. Reddy's Reports Q2 Margins At 20.6%, Reaffirms FY27 EBITDA Margin Forecast Above 20%

Market snapshot: Dr. Reddy's Laboratories reported an EBITDA margin of 20.6% for Q2 FY27, with total quarterly EBITDA reaching ₹1,783 crore. Despite margin compression in North American generic formulations, the management reiterated its guidance to keep full-year FY27 EBITDA margins above 20%.

Data Snapshot

• Quarterly EBITDA reached ₹1,783 crore, yielding an EBITDA margin of 20.6% for Q2 FY27.
• Consolidated Q2 FY27 revenue stood at ₹8,671 crore, representing a slight 1.5% YoY decline.
• Net profit for the second quarter came in at ₹913.4 crore amid pricing pressure in US generics.

What's Changed

• Q2 FY27 EBITDA margin contracted to 20.6% from 26.7% in Q2 FY26 due to Lenalidomide exclusivity moderation and US price competition.
• Consolidated top-line revenue moderated 1.5% YoY to ₹8,671 crore compared to ₹8,805.1 crore in the year-ago period.

Key Takeaways

• Operating profit margin held at 20.6%, demonstrating operational resilience despite high base effects in North America.
• Reaffirmation of the FY27 EBITDA margin floor above 20% indicates cost control and product mix optimization.
• Growth momentum in India and Emerging Markets acts as a structural counterweight to generic pricing headwinds in developed markets.

SAHI Perspective

Dr. Reddy's Q2 FY27 performance highlights a transitional phase in its product portfolio. As key generic exclusivity windows in North America mature, the company is rebalancing profitability through specialty products, biosimilars, and higher-margin branded formulations in India and emerging geographies. Reassuring the market with a baseline FY27 EBITDA margin target of over 20% underscores confidence in operational execution.

Market Implications

The margin floor reassurance provides support for valuation multiples in the pharmaceutical sector. Investors will monitor execution in biosimilar launches and double-digit domestic growth to gauge if margin momentum can expand back toward historical mid-20s levels.

Trading Signals

Market Bias: Neutral

While Q2 FY27 EBITDA margin contracted to 20.6% YoY, management's explicit commitment to defense above 20% for FY27 limits operational downside, establishing a balanced risk-reward profile.

Overweight: India Branded Formulations, Emerging Markets Generics

Underweight: US Generic Formulations

Trigger Factors:

• Biosimilar launch timelines in Europe and US
• Price erosion stability in North American generics
• Sustained 15%+ YoY growth in India finished dosage sales

Time Horizon: Near-term (0-3 months)

Industry Context

Indian pharmaceutical majors are navigating a structural shift in US generics where key exclusivity wind-downs require rapid commercialization of complex injectables and biosimilars. In this environment, defense of EBITDA margins above 20% signals disciplined R&D allocation and lean manufacturing.

Key Risks to Watch

• Accelerated price erosion in North American base generic portfolio
• Regulatory scrutiny or inspection delays at key manufacturing facilities
• Currency volatility across key Emerging Market operating regions

Recent Developments

In H1 FY27, Dr. Reddy's reported a 17% YoY increase in India market revenues to ₹3,568.4 crore and a 27% increase in Emerging Markets sales to ₹3,892.3 crore, mitigating weakness in North America.

Closing Insight

Defending a 20%+ EBITDA margin floor amid North American pricing head-winds confirms Dr. Reddy's strategic transition toward high-barrier complex products and strong regional brand equity.

High Performance Trading with SAHI.